NSW emergency visits tied to unapproved peptide use climb to 217 a month as retatrutide leads

Emergency departments in New South Wales are seeing a fast rise in visits linked to unapproved peptide use, state health officials said on October 19. Surveillance data count 1,180 presentations between July 2025 and September 2026, climbing from five in the first month to 217 in the last. Retatrutide, an experimental weight loss drug sold online, was named in most of them. NSW Health is urging people not to buy peptides from social media, online stores, overseas suppliers or informal sellers, and to talk to a doctor first.

What the emergency data show

The figures come from a report by the NSW Centre for Epidemiology and Evidence, published on October 17 and released with a ministerial statement two days later. Analysts searched triage notes from 88 public hospital emergency departments for mentions of retatrutide, the word peptide, and other names such as BPC 157, TB 500, CJC 1295, GHK Cu, ipamorelin and melanotan. Only people aged 16 and over were counted. The report found 833 presentations, or 71%, that mentioned retatrutide alone. Another 445, or 38%, used the general word peptide or other unapproved names, and 98 mentioned both. Monthly counts were rare at the start, then rose steadily through 2026 to 217 in September. Just under one in five visits, 18%, ended with a hospital admission.

The most common reasons recorded at the emergency desk were gastrointestinal problems such as abdominal pain, nausea and vomiting, followed by heart related problems including chest pain, and then allergic reactions, anaphylaxis and other medicine related harms. Most patients were young. A third were aged 25 to 34, a quarter were 35 to 44, and another quarter were 16 to 24. Men and women were almost evenly split. The busiest emergency departments were in south western, south eastern and western Sydney. NSW Health also tracks calls to the state Poisons Information Centre and reports of serious illness from clinicians, which include kidney damage and liver injury. When a likely case is found, the department works with the Therapeutic Goods Administration and sometimes the police to trace the product.

What the numbers cannot tell us

The report is careful about its limits. A visit is counted when a patient mentions peptides at triage and a nurse writes it down, so the data show that unapproved peptide use was noted, not that it caused the visit. Some entries refer to past use only. The count is of visits, not people, so one person who came back three times appears three times. Severe cases may be missed, because triage notes are often brief when a patient is very unwell. The authors could not estimate how many cases slipped through, and they warn that growing awareness among nurses may itself have pushed the numbers up. Even so, a rise from single digits to more than two hundred a month is hard to explain by note taking alone.

Even so, a rise from single digits to more than two hundred a month is hard to explain by note taking alone.

The products themselves are the other unknown. None of the peptides in the report is approved in Australia for any use, NSW Health said, so nothing sold as retatrutide, BPC 157 or the others has been checked by the regulator. The department warned that these products may hold unknown or harmful ingredients, may be mislabeled, or may contain a different strength from the one advertised. Chief Health Officer Kerry Chant put it plainly: "A professional looking website, a label, purity claim, reviews, or influencer endorsement is not proof of what is inside the product." She added that contents and strength may vary between products carrying the same label. That makes any single emergency visit hard to pin on one compound.

Why retatrutide dominates

Retatrutide is an experimental weekly injection from Eli Lilly that targets three hormone receptors involved in appetite and metabolism. It is still in clinical trials and has no approval in Australia, the United States or elsewhere, which means every vial sold to the public comes from the gray market. Its appearance in 71% of presentations matches what researchers see online. A recent American study of Reddit posts found thousands of people describing their own use, and short video platforms have struggled with the same names, as shown when TikTok blanked peptide searches for retatrutide and others. Demand for approved weight loss drugs is high too: a 2025 state survey found about 8% of NSW adults reported current use of GLP 1 medicines.

Australia has already moved against unofficial copies of weight loss drugs. Regulators ended the compounding of GLP 1 copies in 2024, and the NSW report says the TGA has made unapproved peptides a compliance focus, citing concerns about quality, sterility and dosing accuracy. Health Minister Ryan Park said that "even when a product looks professional or comes in convincing packaging, that does not guarantee it is safe for use." The state's message is that legitimate access runs through a registered medicine prescribed by an Australian practitioner. NSW Health says patients should be able to talk with that practitioner, who should be willing to discuss options other than peptides. A product bought from an overseas website or an influencer link has no such check.

What NSW Health tells people to do

The advice in the state government release is short. Talk about health goals with a usual doctor, since there may be safe, evidence based options. Use only approved peptide products prescribed by a qualified Australian practitioner, and check with the prescriber that the product is a registered medicine. Anyone already using an unprescribed peptide should speak to a health professional before the next injection. Patients should also tell their treating team about peptide use before surgery or other treatment, because serious complications can occur when these products mix with other medicines. In an emergency, people should call Triple Zero, and the Poisons Information Centre answers questions at any hour.

For readers outside Australia, the NSW data are one of the first official counts of hospital visits tied to the peptide trend. In the United States, policy is moving the other way for some compounds. A plan to widen pharmacy compounding of certain peptides has been under White House review, though retatrutide is not part of it. The Australian numbers do not show what would happen under such a policy, because they reflect products with no oversight at all. They do show that unapproved peptide use is large enough to reach hospital records in volume, and that the people affected are mostly young adults. NSW Health says it will keep monitoring presentations, poison calls and clinician reports.

Conclusion

NSW emergency departments recorded 1,180 visits linked to unapproved peptide use in fifteen months, with monthly counts rising from five to 217 and retatrutide named in most of them. The data cannot prove that peptides caused each visit, and the true number may be higher. NSW Health's advice is clear: none of these peptides is approved in Australia, their contents cannot be trusted, and anyone using them should talk to a doctor before the next dose.